Peter Rahmer - 13 Jan 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Reporting relationship: Chief Corporate Development Officer
Issuer ticker: RLAY
Reported as of: 13 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jan 2026, 16:13:45 UTC
Prior SEC filing: 30 Oct 2025
Next SEC filing: 29 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Soo-Yeun Lim, as Attorney-in-Fact

Key filing fact

Peter Rahmer filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 15 Jan 2026.

Key facts

This page summarizes Peter Rahmer's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jan 2026, 16:13.

Change

Previous filing in this sequence was filed on 30 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001959229 Primary reporting owner

Rahmer Peter

Relationship: Chief Corporate Development Officer
Address: C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE
Signature: /s/ Soo-Yeun Lim, as Attorney-in-Fact
Signature date: 15 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLAY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +475,000
Change %
Price: $0.000000
Shares after: 475,000
Date: 13 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 475,000
Exercise price: $7.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date.

SEC remarks

Chief Corporate Development Officer